MN-166 (Ibudilast) Emerging Drug Insight and Market Forecast - 2032

“MN-166 (Ibudilast) Emerging Drug Insight and Market Forecast - 2032”report provides comprehensive insights about MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis in seven major markets. A detailed picture of the MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MN-166 (Ibudilast) market forecast analysis for Amyotrophic Lateral Sclerosis in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

MN-166 (Ibudilast) is an orally bioavailable, first-in-class, small-molecule inhibitor of phosphodiesterases (PDE) 4 and 10 and an inhibitor of macrophage migration inhibitor (MIF) that inhibits pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and upregulate the anti-inflammatory cytokine IL-10. It attenuates stimulated glial cells, which in some neurological conditions play a major role. The anti-neuroinflammatory and neuroprotective activities of MN-166 (Ibudilast) have been shown in preclinical and clinical studies to provide the basis for treating progressive neurological disorders such as Amyotrophic Lateral Sclerosis. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves the redirection of an approved drug, MN-166 (Ibudilast), which was first approved in Japan more than 20 years ago. The MN-166 (Ibudilast) portfolio, which includes the Phase II-staged lead drug compound and proprietary analogs, represents a novel, first-in-class, non-opioid drugs for drug addiction treatment, progressive multiple sclerosis, and pain.

MN-166 (Ibudilast)) achieved positive results in a completed Phase II clinical trial study designed to evaluate the safety, tolerability, and clinical responsiveness of MN-166 (Ibudilast) (60 mg/day) when administered as an adjunct to riluzole (100 mg/day) in 60 subjects with Amyotrophic Lateral Sclerosis. Following this, the company decided to proceed further with the next phase of the clinical trial study.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MN-166 (Ibudilast) description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.
• Elaborated details on MN-166 (Ibudilast) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MN-166 (Ibudilast) research and development activities in Amyotrophic Lateral Sclerosis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MN-166 (Ibudilast).
• The report contains forecasted sales of MN-166 (Ibudilast) for Amyotrophic lateral sclerosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.
• The report also features the SWOT analysis with analyst views for MN-166 (Ibudilast) in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MN-166 (Ibudilast) Analytical Perspective

In-depth MN-166 (Ibudilast) Market Assessment

This report provides a detailed market assessment of MN-166 (Ibudilast) for Amyotrophic lateral sclerosis in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

MN-166 (Ibudilast) Clinical Assessment

The report provides the clinical trials information of MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Amyotrophic lateral sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MN-166 (Ibudilast) dominance.
• Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to MN-166 (Ibudilast) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MN-166 (Ibudilast) in Amyotrophic Lateral Sclerosis.
• Our in-depth analysis of the forecasted sales data of MN-166 (Ibudilast) from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MN-166 (Ibudilast) in Amyotrophic Lateral Sclerosis.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of MN-166 (Ibudilast)?
• What is the clinical trial status of the study related to MN-166 (Ibudilast) in Amyotrophic lateral sclerosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MN-166 (Ibudilast) development?
• What are the key designations that have been granted to MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis?
• What is the forecasted market scenario of MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis?
• What are the forecasted sales of MN-166 (Ibudilast) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to MN-166 (Ibudilast) for Amyotrophic Lateral Sclerosis?
• Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?